§CognitiveResearch protocol
PE-22-28.
PE-22-28 is a synthetic heptapeptide (sequence: GVSWGLR) derived from the sortilin propeptide, engineered as a potent and selective antagonist of TREK-1 potassium channels[4]. Preclinical studies d...
Research Use Only. PeptiJournal supports private research documentation and calculation support. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.
Cited diluent3 mL
Cited protocol example—review and confirm.
Reference syringe capacity
Concentration
3,333.333
mcg/mL
Per event
50 mcg
7 events/week
Vials projected
—
No finite cited cycle
Calculated volume reference
1.5 units
1mL syringe
PE-22-28
1.5u(0.015 mL)
Daily
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2
50 µg
Units / volume1.5 units (0.015 mL)
Weeks 3–4
100 µg
Units / volume3 units (0.03 mL)
Weeks 5–8
100 µg
Units / volume3 units (0.03 mL)
Weeks 9–12 (Optional)
150 µg
Units / volume4.5 units (0.045 mL)
Weeks 13–16 (Optional)
200 µg
Units / volume6 units (0.06 mL)
| Phase | Daily reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 | 50 µg | 1.5 units (0.015 mL) |
| Weeks 3–4 | 100 µg | 3 units (0.03 mL) |
| Weeks 5–8 | 100 µg | 3 units (0.03 mL) |
| Weeks 9–12 (Optional) | 150 µg | 4.5 units (0.045 mL) |
| Weeks 13–16 (Optional) | 200 µg | 6 units (0.06 mL) |
Cited guide source: View source